Codexis (CDXS) Return on Capital Employed (2011 - 2026)
Codexis (CDXS) recorded quarterly Return on Capital Employed of 23.68% in Q1 2026, up 37.28% quarter-over-quarter from 37.75% in Q4 2025, and up 3318.0% on a YoY basis from 0.69% in Q1 2025.
Codexis (CDXS) Return on Capital Employed (2011 - 2026) Analysis & Trends
Codexis' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 23.68% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 3318.0% year-over-year to 23.68%; the TTM figure through Mar 2026 stood at 23.68% (up 3318.0% YoY), while the FY2025 annual figure was 33.91%, up 1521.0% from the prior year.
- Return on Capital Employed was 23.68% for Q1 2026 at Codexis, up from 37.75% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 9.78% in Q2 2022 to a low of 62.06% in Q4 2023.
- Historically, Return on Capital Employed has averaged 38.68% across 5 years, with a median of 46.83% in 2024.
- The sharpest annual moves came in 2023 and 2026: Return on Capital Employed sank 4406 bps in 2023, then soared 3318 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 18.0% in 2022, then tumbled by 245 bps to 62.06% in 2023, then gained by 25 bps to 46.83% in 2024, then climbed by 19 bps to 37.75% in 2025, then surged by 37 bps to 23.68% in 2026.
- The last three Return on Capital Employed figures came in at 23.68% (Q1 2026), 37.75% (Q4 2025), and 52.95% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Codexis | 236.00 Mn | 170.86 Mn | 13.18 Mn | -23.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.68% |
| Dec 31, 2025 | -37.75% |
| Sep 30, 2025 | -52.95% |
| Jun 30, 2025 | -48.38% |
| Mar 31, 2025 | -56.85% |
| Dec 31, 2024 | -46.83% |
| Sep 30, 2024 | -48.49% |
| Jun 30, 2024 | -60.23% |
| Mar 31, 2024 | -49.39% |
| Dec 31, 2023 | -62.06% |
| Sep 30, 2023 | -57.39% |
| Jun 30, 2023 | -34.06% |
| Mar 31, 2023 | -25.60% |
| Dec 31, 2022 | -18.00% |
| Sep 30, 2022 | -15.75% |
| Jun 30, 2022 | -9.78% |
| Mar 31, 2022 | -10.38% |
| Dec 31, 2021 | -11.15% |
| Sep 30, 2021 | -8.71% |
| Jun 30, 2021 | -12.56% |